RedHill Biopharma Announces Unanimous Positive DSMB Recommendation for Continuation of the Phase III Study with RHB-104 for Crohn’s Disease Aug 1, 2017 Life Science
WuXi AppTec Merges Formulation/Finishing Services into API Manufacturing Division Jul 31, 2017 Life Science
CSPC Pharma Signs $118.5 Million Deal for Two Molecules from University of Texas Jul 27, 2017 Life Science
Resverlogix Receives Approval Pathway from the FDA as to the Inclusion of USA Patients in the Phase 3 BETonMACE Trial Jul 26, 2017 Life Science
Resverlogix Files 2017 Year-End Disclosure Documents and Announces Plans to Host a Symposium at the European Society of Cardiology Congress 2017 Jul 26, 2017 Life Science
Nanjing Frontier Acquires Rights to Rockefeller University HIV/AIDS Antibody Jul 25, 2017 Life Science
DelMar Pharmaceuticals Receives Approval from China’s Human Genetic Resources Administration to Initiate Phase 2 Clinical Trial in Newly Diagnosed GBM Jul 25, 2017 Life Science
Cardinal Health Plans $1.5 Billion Sale of China Drug Distribution Business Jul 20, 2017 Life Science
RedHill Biopharma Announces Last Patient Visit in BEKINDA® Phase II Study for IBS-D Jul 19, 2017 Life Science
DelMar Pharmaceuticals Announces Completion of First Site Initiation Visit for STAR-3 Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM Jul 19, 2017 Life Science
